The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany
Introduction Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/safety of empagliflozin.Research design and methods...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-04-01
|
Series: | BMJ Open Diabetes Research & Care |
Online Access: | https://drc.bmj.com/content/8/1/e001486.full |
id |
doaj-5f456ea4af564371a50893a1c20901f8 |
---|---|
record_format |
Article |
spelling |
doaj-5f456ea4af564371a50893a1c20901f82021-06-10T10:07:13ZengBMJ Publishing GroupBMJ Open Diabetes Research & Care2052-48972020-04-018110.1136/bmjdrc-2020-001486The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in GermanyThomas Danne0Jochen Seufert1Christian Wagner2Kerstin König3Dirk Raddatz4Rosmarie Weber-Lauffer5Diether Erath6Jost Hilgenberg7Carsten Spies8Maximilian Gabler9Johannes Foersch10Ludwin Ley11Diabeteszentrum für Kinder und Jugendliche, Kinderkrankenhaus auf der Bult, Hannover, GermanyFreiburg University Hospital, Freiburg, GermanyPraxis Wagner, Saaldorf-Surheim, GermanyMedizinische Kompetenzkollegium, Kamen, GermanyDepartment of Gastroenterology and Endocrinology, University of Göttingen, Gottingen, GermanySchwerpunktpraxis Diabetologie, Karlsruhe, GermanyPraxis für Innere Medizin, Rottweil, GermanyGemeinschaftspraxis, Nienburg - Locum - Landsbergen, GermanySt Vincenz Krankenhaus, Limburg, GermanyBoehringer Ingelheim Pharma GmbH und Co KG, Ingelheim, GermanyBoehringer Ingelheim Pharma GmbH und Co KG, Ingelheim, GermanyBoehringer Ingelheim Pharma GmbH und Co KG, Ingelheim, GermanyIntroduction Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/safety of empagliflozin.Research design and methods Data from the Diabetes Patienten Verlaufsdokumentation (DPV)/Diabetes Versorgungsevaluation (DIVE) registries on 9571 adults with T2DM (registered in 2014–2019) receiving empagliflozin were used. Patients were grouped according to the following: early users (group 1; n=505) received empagliflozin before the EMPA-REG OUTCOME study publication (mid-September 2015); intermediate users (group 2; n=2961) started empagliflozin after the EMPA-REG OUTCOME publication but before the European Medicines Agency label change (from mid-September 2015 to mid-January 2017); and late users (group 3; n=6105) started empagliflozin after mid-January 2017. Data on clinical and treatment characteristics were collected.Results Over time, the proportion of recipients aged <65 years decreased (71.1% vs 54.4% among early and late adopters), male patients increased (from 50.9% to 66.5%), body mass index (mean±SD) decreased (from 35.5±6.7 to 32.7±6.6 kg/m2), proportion with cardiovascular morbidities increased (from 20.4% to 26.4%), and mean estimated glomerular filtration rate decreased (from 83.2±19.5 to 78.5±21.1 mL/min/1.73 m2) (all p<0.001). Patients increasingly received empagliflozin in combination with metformin (60.8% vs 68.6% of early and late adopters; p<0.001), glucagon-like peptide-1 (GLP-1) agonists (11.0 vs 14.1%; p<0.001) or insulin (34.3% vs 49.9%; p<0.001). Empagliflozin was generally added to existing antidiabetic regimens. Six months after empagliflozin initiation, the mean glycated hemoglobin (HbA1c) decreased by 0.4%, the proportion of patients with HbA1c <6.5% increased (19.2% vs 12.8%), and the mean fasting plasma glucose decreased (155.8±49.7 vs 168.0±55.1 mg/dL) (all p<0.001). No significant changes in rates of severe hypoglycemia and no cases of diabetic ketoacidosis were seen.Conclusions Over time, empagliflozin is being prescribed to a broader patient range in routine practice, is usually added to existing antidiabetic regimens, and is increasingly used in combination with metformin, GLP-1 agonists and/or insulin. Empagliflozin had a beneficial effect on glycemic control, with no increase in hypoglycemia.https://drc.bmj.com/content/8/1/e001486.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Thomas Danne Jochen Seufert Christian Wagner Kerstin König Dirk Raddatz Rosmarie Weber-Lauffer Diether Erath Jost Hilgenberg Carsten Spies Maximilian Gabler Johannes Foersch Ludwin Ley |
spellingShingle |
Thomas Danne Jochen Seufert Christian Wagner Kerstin König Dirk Raddatz Rosmarie Weber-Lauffer Diether Erath Jost Hilgenberg Carsten Spies Maximilian Gabler Johannes Foersch Ludwin Ley The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany BMJ Open Diabetes Research & Care |
author_facet |
Thomas Danne Jochen Seufert Christian Wagner Kerstin König Dirk Raddatz Rosmarie Weber-Lauffer Diether Erath Jost Hilgenberg Carsten Spies Maximilian Gabler Johannes Foersch Ludwin Ley |
author_sort |
Thomas Danne |
title |
The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany |
title_short |
The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany |
title_full |
The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany |
title_fullStr |
The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany |
title_full_unstemmed |
The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany |
title_sort |
dive/dpv registries: evolution of empagliflozin use in clinical practice in germany |
publisher |
BMJ Publishing Group |
series |
BMJ Open Diabetes Research & Care |
issn |
2052-4897 |
publishDate |
2020-04-01 |
description |
Introduction Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/safety of empagliflozin.Research design and methods Data from the Diabetes Patienten Verlaufsdokumentation (DPV)/Diabetes Versorgungsevaluation (DIVE) registries on 9571 adults with T2DM (registered in 2014–2019) receiving empagliflozin were used. Patients were grouped according to the following: early users (group 1; n=505) received empagliflozin before the EMPA-REG OUTCOME study publication (mid-September 2015); intermediate users (group 2; n=2961) started empagliflozin after the EMPA-REG OUTCOME publication but before the European Medicines Agency label change (from mid-September 2015 to mid-January 2017); and late users (group 3; n=6105) started empagliflozin after mid-January 2017. Data on clinical and treatment characteristics were collected.Results Over time, the proportion of recipients aged <65 years decreased (71.1% vs 54.4% among early and late adopters), male patients increased (from 50.9% to 66.5%), body mass index (mean±SD) decreased (from 35.5±6.7 to 32.7±6.6 kg/m2), proportion with cardiovascular morbidities increased (from 20.4% to 26.4%), and mean estimated glomerular filtration rate decreased (from 83.2±19.5 to 78.5±21.1 mL/min/1.73 m2) (all p<0.001). Patients increasingly received empagliflozin in combination with metformin (60.8% vs 68.6% of early and late adopters; p<0.001), glucagon-like peptide-1 (GLP-1) agonists (11.0 vs 14.1%; p<0.001) or insulin (34.3% vs 49.9%; p<0.001). Empagliflozin was generally added to existing antidiabetic regimens. Six months after empagliflozin initiation, the mean glycated hemoglobin (HbA1c) decreased by 0.4%, the proportion of patients with HbA1c <6.5% increased (19.2% vs 12.8%), and the mean fasting plasma glucose decreased (155.8±49.7 vs 168.0±55.1 mg/dL) (all p<0.001). No significant changes in rates of severe hypoglycemia and no cases of diabetic ketoacidosis were seen.Conclusions Over time, empagliflozin is being prescribed to a broader patient range in routine practice, is usually added to existing antidiabetic regimens, and is increasingly used in combination with metformin, GLP-1 agonists and/or insulin. Empagliflozin had a beneficial effect on glycemic control, with no increase in hypoglycemia. |
url |
https://drc.bmj.com/content/8/1/e001486.full |
work_keys_str_mv |
AT thomasdanne thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT jochenseufert thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT christianwagner thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT kerstinkonig thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT dirkraddatz thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT rosmarieweberlauffer thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT diethererath thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT josthilgenberg thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT carstenspies thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT maximiliangabler thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT johannesfoersch thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT ludwinley thedivedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT thomasdanne divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT jochenseufert divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT christianwagner divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT kerstinkonig divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT dirkraddatz divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT rosmarieweberlauffer divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT diethererath divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT josthilgenberg divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT carstenspies divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT maximiliangabler divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT johannesfoersch divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany AT ludwinley divedpvregistriesevolutionofempagliflozinuseinclinicalpracticeingermany |
_version_ |
1721385142957637632 |